Tredu. Expert Education. Smarter Trading.

Mastering Equity and Stock Trading, Cryptocurrency Investment, Digital Assets and Global Forex Market Analysis: The Ultimate Masterclass at Tredu

Gain access to expert-led courses, live market analysis, and educational webinars that turn complex concepts into actionable strategies.Learn how to trade smarter and join our community of successful traders, building sustained financial growth.

Financial News

Maintain market dominance with real-time updates and expert analysis.
Our educators provide focused coverage across stock trading, forex markets, and crypto investing. We translate the latest financial news into practical knowledge, empowering you to trade smarter and achieve superior execution.

Proprietary Trading Strategies and
Quantitative Analysis

Sharpen your execution skills and gain a decisive edge with in-depth insights delivered by our top trading educators. Explore proven trading strategies, anticipate current market trends, and leverage expert analysis specifically designed to support your trading education and accelerate your path to sustained market success.

Tredu Team | Insights

Boston Scientific (BSX): Bullish Analyst Sets $75 Target

Boston Scientific (BSX): Bullish Analyst Sets $75 Target

Analyst Bullish on Boston Scientific (NYSE: BSX) Despite Recent Stock Dip Stifel Nicolaus analyst Rick Wise set a $75.00 price target for Boston Scientific, suggesting a 46.86% upside from its $51.07 trading price at the time. Despite a positive analyst outlook, Boston Scientific has faced significant stock declines, including a 44.80% drop over the past year and a 39.50% year-to-date decrease. Boston Scientific (NYSE: BSX) is a global company that develops and sells medical devices. These devices are used in many medical fields, helping doctors treat a wide range of conditions. Boston Scientific operates in a competitive industry with other major medical technology firms, all working to create innovative healthcare solutions. On May 27, 2026, Stifel Nicolaus analyst Rick Wise adjusted the price target for Boston Scientific to $75.00. At that time, the stock was trading at $51.07 per share. This new target suggests a potential increase of about 46.86% from its price when the report was released, showing the analyst's confidence in its future. This analyst update comes as Boston Scientific faces significant price challenges. The company's stock has declined 44.80% over the past year and has dropped 39.50% since the start of the year. On one recent day, the stock fell 11.92% to $50.77, touching a new 52-week low of $50.58 during the session. Wall Street analysts are optimistic, as highlighted by Zacks. The stock has an average brokerage recommendation of 1.32, which is close to a Strong Buy. Out of 31 firms covering the stock, 24 rate Boston Scientific a Strong Buy, and an additional four give it a Buy rating.

Tredu Team | Insights

Editas Medicine (NASDAQ: EDIT) Maintains Buy Rating Amid Promising Clinical Data and Capital Raise

Editas Medicine (NASDAQ: EDIT) Maintains Buy Rating Amid Promising Clinical Data and Capital Raise

Cowen & Co. has reiterated its Buy rating for Editas Medicine, highlighting its potential in the genome editing space. The company's lead candidate, EDIT-401, shows compelling preclinical data as a potential one-time treatment for hyperlipidemia. Editas Medicine is conducting a public offering to raise approximately $125.00 million in gross proceeds to fund its ongoing research and development. On May 27, 2026, analyst firm Cowen & Co. maintained its Buy rating for Editas Medicine (NASDAQ: EDIT), with the stock priced at $3.68. Editas Medicine is a clinical-stage genome editing company. It focuses on developing treatments for a range of serious diseases by correcting disease-causing genes. The firm’s positive rating is supported by compelling preclinical data for Editas’s lead candidate, EDIT-401. As highlighted by GlobeNewswire, data presented at the 94th European Atherosclerosis Society Congress showed significant results. A single dose in non-human primates caused mean reductions of approximately 90% or greater in LDL-cholesterol and other harmful lipids, underscoring the potential of this gene therapy. Further data from the American Society of Gene and Cell Therapy 2026 Annual Meeting supports EDIT-401 as a potential one-time treatment for hyperlipidemia. This is a condition where there are high levels of fats, like cholesterol, in the blood. Editas expects to submit a Clinical Trial Notification for EDIT-401 by mid-2026, moving closer to human trials for this innovative biotechnology stock. To fund its research, Editas announced a public offering to raise capital. The company is selling over 55.50 million shares of its common stock. Each share is sold with an accompanying warrant at a combined price of $2.25, with the goal of raising approximately $125.00 million in gross proceeds. The offering also includes warrants to purchase an additional 55.50 million shares. A warrant gives an investor the right, but not the obligation, to buy a stock at a set price before a specific date. If all warrants are exercised, Editas could raise an additional $194.40 million.

Tredu Team | Insights

Associated Banc-Corp (NYSE: ASB) Insider Trading: Executive Sells Shares Near 52-Week High

Associated Banc-Corp (NYSE: ASB) Insider Trading: Executive Sells Shares Near 52-Week High

An executive at Associated Banc-Corp (NYSE: ASB) sold 9,299 shares at an average price of $28.26, reducing their holding to 21,385 shares. Despite the stock trading near its 52-week high, a GF Value analysis suggests the regional bank stock is undervalued with an estimated fair value of $28.73. This transaction is part of a broader trend of $1.0 million in insider sales over the last three months, offering insights into executive sentiment. Associated Banc-Corp (NYSE: ASB) is a prominent bank holding company with a market capitalization of approximately $4.65 billion. This regional bank provides a comprehensive range of banking and financial services to individuals and businesses. It operates primarily in the Midwest region of the United States, facing competition from other regional and national banks in the competitive financial sector. The main focus of this investment analysis is on a recent insider transaction. On May 26, 2026, DeLoye Dennis, the Executive Vice President of ASB, sold 9,299 shares. The average sale price for this transaction was $28.26 per share. Following this significant sale, the executive's holding in the company stands at 21,385 shares. This executive sale follows a recent increase in the stock's price. On May 20, 2026, shares of ASB rose by 3.0% to $27.99. The stock's 52-week trading range is between $22.48 and $29.52, placing the insider sale price near the upper end of this range. The current market price for ASB stock is $28.05. Despite ASB stock trading near its 52-week high, a GF Value analysis, as highlighted by Gurufocus, suggests the regional bank stock is currently undervalued. Its estimated fair value is $28.73. The company also boasts a GF Score of 71 out of 100, which is considered an above-average rating for potential future performance and investment potential. This specific insider transaction is part of a larger trend of insider sales at Associated Banc-Corp. Over the last three months, insiders have collectively sold a total of $1.0 million worth of ASB stock. Such insider activity is often closely monitored by investors for valuable insights into executive sentiment regarding the company's future prospects and stock outlook.

Connect with Verified Trading
Educators for Tailored Mentorship
Across All Trading Styles

ADVANCED SEARCH

108 results

Top Brokers

Secure Your Trading Journey with the Right Broker

Advertisement for tredu.com - trading platform

Proud Media Partners of

Cyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumCyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation Forum